 BRISBANE, Calif., Feb. 24, 2022 PRNewswire -- GT Biopharma, Inc. NASDAQ: GTBP, a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Companys proprietary natural killer NK cell engager, TriKE protein biologic technology platform, announced today that GT Biopharma will be participating in the following upcoming medical conferences: Abstract and poster presentation details are as follows: ESMO Targeted Anticancer Therapies Congress TAT March 7-8, 2022 Title: Driving NK cell immunotherapy against NSCLC, in the context of hypoxia, using Tri-specific Killer Engager TriKE Abstract Number: 250 Session: Immunotherapy Presentation Type: Poster Session Date and Time: March 7, 9:20AM CET On-demand e-poster display Location: Virtual Poster Board Number: 17P 48th Annual European Society for Blood and Marrow Transplantation EBMT March 19-23, 2022 Title: A Tri-specific Killer Engager TriKE against B7-H3 enhances NK cell mediated killing of multiple myeloma Abstract Number: AS-EBMT-2022-00508 Session: New Drugs- and Cell-Based Immune Therapies Presentation Type: Poster Session Date and Time: March 19, 2022, 9:50 AM CET Location: Prague Congress Center, Czech Republic Poster Board Number: P153 American Association for Cancer Research AACR Annual Meeting April 8-13, 2022 Title: GTB-5550 cam16-IL15-camB7H3 Tri-specific Killer Engager TriKE drives natural killer cell activation and antibody dependent cellular cytotoxicity against head and neck squamous cell carcinomas Abstract Number: Abstract control number 3334, permanent abstract number 3435 Session: Clinical Research Excluding Trials, Combination Immunotherapies Therapeutic Antibodies Presentation Type: Poster Session Date and Time: April 12, 2022 1:30 PM 5:00 PM Location: Ernest N. 